JohnHar Posted - 4 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $OGN $ALKS

Galacticstock Posted - 1 week ago

$ALKS Just watched a presentation on Lybalvi. Sounds like a winner 🥇

anachartanalyst Posted - 2 weeks ago

$ALKS https://anachart.com/wp-content/uploads/ana_temp/1730804484_soc-img.jpg

ChessGM Posted - 10/26/24

$ALKS Upcoming Earnings Alert for 10/29/2024 Neutral (5.5) Alkermes PLC has recently faced challenges in its third-quarter earnings results, as highlighted by multiple reports indicating that both earnings and revenue fell short of market expectations. The company reported a profit of $92.4 million, with earnings per share at 55 cents, which was below analysts' forecasts. Despite these setbacks, there are positive aspects to consider. The growth in net sales of proprietary products, particularly from Vivitrol and Lybalvi, indicates underlying strength in certain segments of Alkermes' portfolio. Moreover, the stock has seen a notable 30% increase over the past three months, aided by a Relative Strength Rating upgrade, suggesting improving technical performance. Analysts are divided, with some emphasizing the stock's potential as undervalued and a candidate for long-term growth, while others remain cautious given the recent earnings miss. Regarding upcoming earnings, Alkermes is set to report its third-quarter financial results on October 24, 2024. The company will host a conference call at 8:00 a.m. ET to discuss the results in detail. Analysts are expected to closely monitor key performance metrics during this call, particularly in light of the recent earnings miss and the company's efforts to navigate market challenges. The anticipation surrounding this report may affect trading activity leading up to the release. In total, there were28 news articlesanalyzed from 15 unique news sources. - Funds were net buyers of $ALKS during the previous reporting quarter. - Top 5 funds with large holdings in $ALKS: * RTW Investments LP $170MM (Market Value). CGMFundScore: 62% * Baker Brothers Advisors LP $101MM (Market Value). Newly initated position. CGMFundScore: 83% * Armistice Capital LLC $65MM (Market Value). CGMFundScore: 80% * Westfield Capital Management Company LP $32MM (Market Value). CGMFundScore: 82% * Mpm Bioimpact LLC $13MM (Market Value). Newly initated position. CGMFundScore: 42% - Last 10 days performance: -4% - Last 30 days performance: 2% - Last 90 days performance: -4% Follow ChessGM! Do not miss other earnings alerts from ChessGM. Not a financial advice.

FilingFact Posted - 10/25/24

New financial insights available on https://www.filingfact.com/ from yesterdays report of $ALKS With the launch of the new platform we are offering 1 month of FREE Premium Access (worth $49) to the first 100 users! 🥳 💬 We’d love to hear your thoughts—your feedback will help us improving our service to your needs! For any questions, ideas, or support, reach out to us at [email protected] 👉 Join today and be a part of the journey!

Thestocktraderhubzee Posted - 10/25/24

$ALKS JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $26

dachshund36 Posted - 10/25/24

$ALKS Quarterly earnings -2.4% less than expected. Price drops ... now 3%. Buying the dip. Earnings going forward look good. A buy for pharm company at <10 P/E.

737Flyer Posted - 10/24/24

$ALKS just got in! LFG

WeeklyTrader Posted - 10/23/24

What’s the deal with $ALKS? Should we sell? RSI: 51.34% 50-day MA: $27.78 200-day MA: $26.6

StockNipsDaily Posted - 1 month ago

$PSIL Love when people try and own others on this app but are just straight wrong. 😆 @JimmyRussels420 is a a DD-less-clown — 🤡 — making some idiotic assertions tryna flex on folks. Screenshots to prove it since I texted my friends about it when it happened. It was the third top position 🍆💦💦 actively managed 😂 $CMPS $MNMD $CYBN $ALKS

oratocheri Posted - 1 month ago

$ALKS Another interesting potential buy .. any insiders?

DonCorleone77 Posted - 09/23/24

$ALKS Alkermes to present clinical data from its Phase 1b study of ALKS 2680 Alkermes announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2, NT2, and idiopathic hypersomnia, IH, at the European Sleep Research Society's, ESRS, 27th Congress, Sleep Europe 2024, taking place Sept. 24-27, 2024 in Seville, Spain. ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor, OX2R, agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. In an oral presentation and corresponding poster presentation, the company will share data from the cohort of patients with NT2 from the phase 1b, proof-of-concept study evaluating single-dose, oral administration of ALKS 2680. Additionally, the company will present a poster with data from the cohort of patients with IH from the same study. As previously announced, ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo in both cohorts.

Stock_Titan Posted - 09/23/24

$ALKS Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 https://www.stocktitan.net/news/ALKS/alkermes-to-present-positive-clinical-data-from-phase-1b-study-of-0c3cbscbdhtq.html

harmongreg Posted - 09/22/24

Dragonfly Capital - 5 Trade Ideas for Monday: Alkermes, Citigroup, Caterpillar, Neogen and EchoStar https://dragonflycap.com/5-trade-ideas-for-monday-alkermes-citigroup-caterpillar-neogen-and-echostar/ $ALKS $C $CAT $NEOG $SATS

Stock_Titan Posted - 2 months ago

$ALKS Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program https://www.stocktitan.net/news/ALKS/alkermes-announces-launch-of-7th-annual-alkermes-pathways-research-mibq66iuvi2v.html

k_rma Posted - 2 months ago

$PSIL $MNMD $CMPS $ALKS Hopefully the catalyst the field of psychedelics needs. US gov’t grant for clinical trial on psychedelic treatment of PTSD, traumatic brain injury. submission deadline: 10/4/24

StockInvest_us Posted - 2 months ago

Signal alert: $ALKS - Overbought Trend Short (Overvalued) https://stockinvest.us/l/vU1KaZnmwP

Stock_Titan Posted - 08/22/24

$ALKS Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 https://www.stocktitan.net/news/ALKS/alkermes-announces-initiation-of-vibrance-2-phase-2-study-evaluating-bez7uilty6ld.html

RiskVsReward Posted - 3 months ago

$ALKS Look at this chart! 🏆

contangoz Posted - 3 months ago

BLOOMY upbeat on deal $alks

Shlobby Posted - 3 months ago

$ALKS if you get stopped out once cut and try again. Big candle today

kinderspiel Posted - 3 months ago

today $FULC announced the appointment of isabel kalofonos as CCO & heather faulds as chief regulatory affairs & quality assurance officer. together, they will be instrumental in advancing losmapimod towards a new drug application submission & preparing for commercial launch. ms. kalofonos joins fulcrum from $IMGN where she served as senior vice president & chief commercial officer. most recently, ms. faulds served as svp, regulatory affairs at $ALKS

Fullratio Posted - 3 months ago

Healthcare sector stocks with high YoY EPS growth in Q2 2024: $JNJ $ALKS $NVS

kinderspiel Posted - 3 months ago

Aug 15 highest volume of shares traded $EXAS 410.6 k $NTRA 242.7 k $BEAM 158.6 k $ALKS 120.7 k $BPMC 101.0 k

StockInvest_us Posted - 3 months ago

Signal alert: $ALKS - Overbought Trend Short (Overvalued) https://stockinvest.us/l/JYHI4J7oTn

NVDAMillionaire Posted - 07/31/24

$ALKS Alkermes (ALKS): A Diversified Biopharma Poised for Continued Growth http://beyondspx.com/2024/07/31/alkermes-alks-a-diversified-biopharma-poised-for-continued-growth/

Stocksrunner Posted - 07/28/24

$ALKS Alkermes is in the spotlight after its post-earnings bump, with analysts deeming the stock fairly valued. https://stocksrunner.com/symbol/ALKS

Aigner_Andreas Posted - 07/26/24

TD SELL $ALKS at 25.52, Supp 23.01 Resis 28.04 R22 HiLo 34% T1Y 31 buy 2.5 fwdPE 26.6 DIV N/A #Alkermes p #stocks #trading #finance #market

PenkeTrading Posted - 07/25/24

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Alkermes Plc. Is that bullish or bearish? $ALKS #ALKS #nasdaq #tradingsignals #technicalanalysis

Stocksrunner Posted - 07/24/24

Wednesday Watchlist: Top Searched Stocks Here are today’s most searched stocks on stocksrunner.com: $AGEN $PYPL $ALKS $PKG $BBSI Keep an eye on these symbols as trading heats up today!